Progressive Pulmonary Fibrosis (PPF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Progressive Pulmonary Fibrosis (PPF) Market Outlook
Thelansis’s “Progressive Pulmonary
Fibrosis (PPF) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Progressive Pulmonary Fibrosis
(PPF) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Progressive Pulmonary Fibrosis (PPF)
Overview
Progressive
pulmonary fibrosis (PPF) is a lung disease that gets worse over time. It is
caused by scarring of the lungs, which makes it harder to breathe. PPF can
occur in people with any interstitial lung disease (ILD). However, it is more
common in people with certain types of ILD, such as idiopathic non-specific
interstitial pneumonia (iNSIP), connective tissue disease-related ILD
(CTD-ILD), and fibrotic hypersensitivity pneumonitis. PPF is more likely to
occur in older people who have smoked cigarettes, have bronchiectasis (widening
of the airways), have a certain pattern of scarring on their lungs on a
high-resolution computed tomography (HRCT) scan, have not had their disease
improve, or stabilize, have short telomere syndrome, are Black American, or
have gastroesophageal reflux disease (GERD). Certain biomarkers can be measured
in the blood to help identify people who are at risk of developing PPF. These
biomarkers include the MUCB promoter gene, KL-6, CCL-16, matrix
metalloproteinases (MMP1, MMP7, MMP12), periostin, and tissue inhibitors of
metalloproteinases (TIMP).
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment